Brief: Cumberland Pharmaceuticals Received Consideration Related To Breach Of Contract Action With Melinta Therapeutics & Targanta Therapeutics On June 16
22/06/2023 11:05
June 22 (Reuters) - Cumberland Pharmaceuticals Inc
CPIX.O :
* CUMBERLAND PHARMACEUTICALS - ON JUNE 16 RECEIVED
CONSIDERATION
RELATED TO BREACH OF CONTRACT ACTION WITH MELINTA THERAPEUTICS &
TARGANTA THERAPEUTICS
Source text for Eikon: [http://bitly.ws/Jg7Y]
Further company coverage: CPIX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM